Kymera Therapeutics KYMR
NASDAQ KYMR
$110.85 -1.78 (-1.58%)
At close: Oct 22, 2026 · 4:00 PM EDT

Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020)

Updated

Kymera Therapeutics (KYMR) reported Preferred Stock Liabilities of $211.33 million for Q2 2020.

Analysis

Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

At the end of FY2019, Kymera Therapeutics posted Preferred Stock Liabilities of $109.08 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Kymera Therapeutics 10.91 Bn 8.21 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2020 211.33 Mn
Dec 31, 2019 109.08 Mn
Sep 30, 2019 87.79 Mn
API Access

Kymera Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=KYMR&period=max&api_key=YOUR_API_KEY